Loading
ABSK061 is an experimental small-molecule drug from Abbisko Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer, aimed at HER2 and FGFR2.
ABSK061 is a small-molecule drug developed by Abbisko Therapeutics. Its targets are HER2 and FGFR2. ClinicalTrials.gov describes the intervention as: Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer. The largest, NCT06632262, plans to enrol 202 participants with primary completion expected 2029-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.ABSK061 slips into a pocket on HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ABSK061" OR ABSTRACT:"ABSK061") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ABSK061, not a curated reading list.
Shares Abbisko Therapeutics, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares HER2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.